David and Goliath stories are common place throughout history, with some of the more notable instances occurring in the business world. They often involve a smaller, nimble upstart disrupting a large, entrenched player through a combination of grit and ingenuity, particularly in fast-paced industries shaped by technological innovation. More often, however, the little guys simply coexist with the giants by forming a profitable niche that's underserved and underappreciated, a market where they can gain a foothold and grow.
That's the case with one of the best-performing stocks in the biopharma industry today: Santarus (NASDAQ: SNTS). Up around 10% on a recent FDA approval, follow along in the video below as Brenton discusses one of the health care growth stories you've never heard of.
